Your browser doesn't support javascript.
loading
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman, Victoria L; Wan, Elaine; Foo, Shane; Nathan, Mark R; Welti, Jonathan C; Frentzas, Sophia; Vermeulen, Peter B; Preece, Natasha; Springer, Caroline J; Powles, Thomas; Nathan, Paul D; Larkin, James; Gore, Martin; Vasudev, Naveen S; Reynolds, Andrew R.
Afiliación
  • Bridgeman VL; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom.
  • Wan E; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom. The Royal Marsden (RM), London, United Kingdom.
  • Foo S; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom.
  • Nathan MR; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom.
  • Welti JC; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom.
  • Frentzas S; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom. The Royal Marsden (RM), London, United Kingdom.
  • Vermeulen PB; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom. Translational Cancer Research Unit, GZA Hospitals St. Augustinus, Antwerp, Belgium.
  • Preece N; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Springer CJ; Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.
  • Powles T; Experimental Cancer Medicine Centre, Queen Mary University of London, London, United Kingdom.
  • Nathan PD; Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, United Kingdom.
  • Larkin J; The Royal Marsden (RM), London, United Kingdom.
  • Gore M; The Royal Marsden (RM), London, United Kingdom.
  • Vasudev NS; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom. The Royal Marsden (RM), London, United Kingdom. andrew.reynolds@icr.ac.uk N.Vasudev@leeds.ac.uk.
  • Reynolds AR; Tumour Biology Team, The Breast Cancer Now Toby Robins Research Centre, Mary-Jean Mitchell Green Building, The Institute of Cancer Research (ICR), London, United Kingdom. andrew.reynolds@icr.ac.uk N.Vasudev@leeds.ac.uk.
Mol Cancer Ther ; 15(1): 172-83, 2016 Jan.
Article en En | MEDLINE | ID: mdl-26487278
Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in this patient population is limited by drug resistance. It is possible that treatment outcomes in RCC patients could be improved by rationally combining TKIs with other agents. Here, we address whether inhibition of the Ras-Raf-MEK-ERK1/2 pathway is a rational means to improve the response to TKIs in RCC. Using a xenograft model of RCC, we found that tumors that are resistant to sunitinib have a significantly increased angiogenic response compared with tumors that are sensitive to sunitinib in vivo. We also observed significantly increased levels of phosphorylated ERK1/2 in the vasculature of resistant tumors, when compared with sensitive tumors. These data suggested that the Ras-Raf-MEK-ERK1/2 pathway, an important driver of angiogenesis in endothelial cells, remains active in the vasculature of TKI-resistant tumors. Using an in vitro angiogenesis assay, we identified that the MEK inhibitor (MEKI) trametinib has potent antiangiogenic activity. We then show that, when trametinib is combined with a TKI in vivo, more effective suppression of tumor growth and tumor angiogenesis is achieved than when either drug is utilized alone. In conclusion, we provide preclinical evidence that combining a TKI, such as sunitinib or pazopanib, with a MEKI, such as trametinib, is a rational and efficacious treatment regimen for RCC.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridonas / Pirimidinonas / Carcinoma de Células Renales / Inhibidores de la Angiogénesis / Inhibidores de Proteínas Quinasas / Neoplasias Renales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Piridonas / Pirimidinonas / Carcinoma de Células Renales / Inhibidores de la Angiogénesis / Inhibidores de Proteínas Quinasas / Neoplasias Renales Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos